Hangzhou Medimscience Biomedical Technology Co., Ltd. is dedicated to innovative drug development targeting new macrophage targets, which is a new trend and strategy for the next generation of immunotherapy. We have developed a series of innovative drug pipelines mainly for autoimmune diseases such as IBD and cold tumors with high macrophage infiltration. Our strategy is to develop antibody drugs with novel mechanisms of action to treat drug-resistant autoimmune diseases and various ICB and T cell therapy resistant solid cancers, including colon cancer, liver cancer, and gliomas et al. We are also developing dual-target antibodies and combination strategies that integrate chemotherapy, antibody-drug or antibody–drug conjugates, which provide better synergistic effect.
Our Investors
Contact
- Webwww.alquiplus.com
- Tel(0571) 8210 1560
- E-mailservice@medimscience.com
- AddressRoom 1301, Building 3, No. 18 Zhiheng Lane, Xiaoshan District, Hangzhou City, Zhejiang Province, China